Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tecentriq plus nab-paclitaxel/paclitaxel in PD-L1 positive advanced TNBC
CTR20200617Phase 3Terminated
- Sponsor
- Roche
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of atezolizumab in triple-negative breast cancer (TNBC), sponsored by Roche. Started Oct 2021; status: terminated.
02
Drugs
atezolizumab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20200617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200617.